Literature DB >> 15241829

Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Fabrice Bonnet1, Charlotte Lewden, Thierry May, Laurence Heripret, Eric Jougla, Sibylle Bevilacqua, Dominique Costagliola, Dominique Salmon, Geneviève Chêne, Philippe Morlat.   

Abstract

BACKGROUND: Before the introduction of highly active antiretroviral therapy (HAART), malignancies accounted for less than 10% of all deaths among human immunodeficiency virus (HIV)-infected patients. This figure may have increased, and the observed types of malignant disease may have been modified, as a result of decreased occurrence of opportunistic infections, the chronicity of HIV infection, the possible oncogenic role of HIV itself, and the aging of the HIV-infected population.
METHODS: All French hospital wards involved in the management of HIV infection were asked to prospectively document the deaths of HIV-infected patients in the year 2000. Underlying causes of death were defined using a standardized questionnaire.
RESULTS: Of a total of 964 deaths, 269 (28%) were attributable to malignancies. Acquired immunodeficiency virus (AIDS)-related malignancies were the underlying cause of 149 deaths (15%); among these malignancies were non-Hodgkin lymphoma (n = 105 [11%]), noncerebral lymphoma (n = 78 [median CD4 count, 86 x 10(6) per liter; interquartile range [IQR], 35-231 x 10(6) per liter), and primary cerebral lymphoma (n = 27 [median CD4 count, 20 x 10(6) per liter; IQR, 4-109 x 10(6) per liter). Kaposi sarcoma was associated with 40 deaths (4%), and cervical carcinoma was associated with 5 (0.5%). Non-AIDS-related malignancies were the underlying cause of 120 deaths (13%); these non-AIDS-related malignancies included 103 solid tumors (50 respiratory tumors, 19 hepatocarcinomas, 9 digestive tumors, and 6 anal tumors; median CD4 count, 218 x 10(6) per liter; IQR, 108-380 x 10(6) per liter) and 17 hemopathies (12 Hodgkin lymphomas, 4 myeloid leukemias, and 1 myeloma; median CD4 count, 113 x 10(6) per liter; IQR, 56-286 x 10(6) per liter). Compared with patients who died of other causes, patients who died of solid tumors were more likely to be male, to smoke, to be older, and to have higher CD4 counts.
CONCLUSIONS: Malignant disease has been a major cause of death among HIV-infected patients in industrialized nations since the introduction of HAART. Whereas lethal hemopathies and Kaposi sarcoma are associated with advanced immunosuppression, lethal solid tumors can occur in patients with controlled HIV infection. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 15241829     DOI: 10.1002/cncr.20354

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  87 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  Regulation of Nm23-H1 and cell invasiveness by Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhiqiang Qin; Lu Dai; Bryan Toole; Erle Robertson; Chris Parsons
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 3.  Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era.

Authors:  Pierluigi Brugnaro; Erika Morelli; Francesca Cattelan; Andrea Petrucci; Sandro Panese; Franklyn Eseme; Francesca Cavinato; Andrea Barelli; Enzo Raise
Journal:  World J Virol       Date:  2015-08-12

Review 4.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

5.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

Review 6.  Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?

Authors:  Jennifer Totonchy; Ethel Cesarman
Journal:  Curr Opin Virol       Date:  2016-09-23       Impact factor: 7.090

7.  Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.

Authors:  Zhiqiang Qin; Lu Dai; Michael Defee; Victoria J Findlay; Dennis K Watson; Bryan P Toole; Jennifer Cameron; Francesca Peruzzi; Keith Kirkwood; Chris Parsons
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Human immunodeficiency virus and cancer. A population of HIV-infected patients at Hospital de Santa Maria and predictors of cancer.

Authors:  Lígia Sofia Fernandes
Journal:  Germs       Date:  2012-06-01

Review 9.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

10.  Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.

Authors:  Zhiqiang Qin; Patricia Kearney; Karlie Plaisance; Chris H Parsons
Journal:  J Leukoc Biol       Date:  2010-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.